Overcoming cancer therapeutic bottleneck by drug repurposing

Z Zhang, L Zhou, N Xie, EC Nice, T Zhang… - Signal transduction and …, 2020 - nature.com
Ever present hurdles for the discovery of new drugs for cancer therapy have necessitated
the development of the alternative strategy of drug repurposing, the development of old …

In silico models in drug development: where we are

J Piñero, LI Furlong, F Sanz - Current Opinion in Pharmacology, 2018 - Elsevier
Highlights•A variety of computational methods and tools are used in QSP and QST. They
show different degrees of maturity.•PBPK models are well established and applied in a wide …

PharmacoDB: an integrative database for mining in vitro anticancer drug screening studies

P Smirnov, V Kofia, A Maru, M Freeman… - Nucleic acids …, 2018 - academic.oup.com
Recent cancer pharmacogenomic studies profiled large panels of cell lines against
hundreds of approved drugs and experimental chemical compounds. The overarching goal …

Computational pharmacogenomic screen identifies drugs that potentiate the anti-breast cancer activity of statins

JE van Leeuwen, W Ba-Alawi, E Branchard… - Nature …, 2022 - nature.com
Statins, a family of FDA-approved cholesterol-lowering drugs that inhibit the rate-limiting
enzyme of the mevalonate metabolic pathway, have demonstrated anticancer activity …

Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer

KL Thu, J Silvester, MJ Elliott… - Proceedings of the …, 2018 - National Acad Sciences
TTK protein kinase (TTK), also known as Monopolar spindle 1 (MPS1), is a key regulator of
the spindle assembly checkpoint (SAC), which functions to maintain genomic integrity. TTK …

Modeling drug mechanism of action with large scale gene-expression profiles using GPAR, an artificial intelligence platform

S Gao, L Han, D Luo, G Liu, Z Xiao, G Shan, Y Zhang… - BMC …, 2021 - Springer
Background Querying drug-induced gene expression profiles with machine learning method
is an effective way for revealing drug mechanism of actions (MOAs), which is strongly …

SYNERGxDB: an integrative pharmacogenomic portal to identify synergistic drug combinations for precision oncology

H Seo, D Tkachuk, C Ho, A Mammoliti… - Nucleic acids …, 2020 - academic.oup.com
Drug-combination data portals have recently been introduced to mine huge amounts of
pharmacological data with the aim of improving current chemotherapy strategies. However …

Signatures of cell death and proliferation in perturbation transcriptomics data—from confounding factor to effective prediction

B Szalai, V Subramanian, CH Holland… - Nucleic Acids …, 2019 - academic.oup.com
Transcriptional perturbation signatures are valuable data sources for functional genomics.
Linking perturbation signatures to screenings opens the possibility to model cellular …

Current trends and future prospects of drug repositioning in gastrointestinal oncology

N Fatemi, M Karimpour, H Bahrami, MR Zali… - Frontiers in …, 2024 - frontiersin.org
Gastrointestinal (GI) cancers comprise a significant number of cancer cases worldwide and
contribute to a high percentage of cancer-related deaths. To improve survival rates of GI …

A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling

DY Wang, DMA Gendoo, Y Ben-David… - Breast cancer …, 2019 - Springer
Background Triple-negative breast cancer (TNBC) represents a heterogeneous group of ER-
and HER2-negative tumors with poor clinical outcome. We recently reported that Pten-loss …